Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche for the buyout

<< Previous

Bullboard Posts

Next >>

Comment by 2O2Ovisionon Oct 28, 2023 10:02am

188 Views

Post# 35705578

RE:RE:RE:RE:RE:Roche for the buyout

I am siding with Roche as well for the simple fact Pancan is likely laying out the ground work with the FDA based on the use of Tecentric (based on Matt's "Roche" comment on the webcast). Merck's keytruda certainly has a history with pela in several indications as well but I'm just following the path of least resistance.

<< Previous

Bullboard Posts

Next >>

Rick Rule's holiday gifts to grow wealth